Compare SHOP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOP | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | Canada | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7B | 199.4B |
| IPO Year | 2014 | 2001 |
| Metric | SHOP | NVO |
|---|---|---|
| Price | $146.91 | $40.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 55 | 14 |
| Target Price | ★ $177.29 | $45.74 |
| AVG Volume (30 Days) | 8.4M | ★ 8.6M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $11,556,000,000.00 | N/A |
| Revenue This Year | $32.51 | N/A |
| Revenue Next Year | $26.40 | $1.30 |
| P/E Ratio | $141.14 | ★ $13.60 |
| Revenue Growth | ★ 30.14 | N/A |
| 52 Week Low | $94.00 | $35.12 |
| 52 Week High | $180.88 | $64.16 |
| Indicator | SHOP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.76 | 52.44 |
| Support Level | $139.89 | $37.61 |
| Resistance Level | $155.55 | $41.41 |
| Average True Range (ATR) | 7.62 | 0.78 |
| MACD | -2.16 | 0.24 |
| Stochastic Oscillator | 31.96 | 49.53 |
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.